ClinicalTrials.gg

Program

HRS-5635

A development code. Also written as “HRS-5635 Injection”, “HRS-5635 Injection (low dose) and Peg-IFN-α” and “HRS-5635 Injection (high dose) and Peg-IFN-α”.

In Jiangsu HengRui Medicine's pipeline, HBV siRNA. Its studies are mostly in Hepatitis B, Chronic, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since May 19, 20263 company-led studies, 3 open or runningNext primary completion: Jun 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine33 open or runningphase 3since May 19, 2026Mar 29, 2023Jun 2028phase 3 · NCT07606950
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-5635, phase 3, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 29, 2023First study: phase 1 study in Hepatitis B, ChronicFirst studyNCT05808374 · 85 planned · China
  2. May 17, 2024Phase 2 study in Hepatitis B, ChronicNCT06425341 · 369 planned · China
  3. May 19, 2026Phase 3 study in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis BPhase 3 reachedNCT07606950 · 540 planned · China

Ahead

  1. Jun 2028Primary completion: phase 3 study in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis BNCT07606950

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“HBV siRNA”the company's pipeline, read by Claude · source
“This study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and immunogenicity of HRS-5635 injection as compared to the placebo arm in nucleos(t)ide analogue-suppressed HBeAg-negative patients with chronic hepatitis B.”study summary, read by Claude · the study

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07606950Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B · China3RecruitingJun 2028540
NCT06425341Hepatitis B, Chronic · China2RecruitingAug 30, 2026369
NCT05808374Hepatitis B, Chronic · China1RecruitingMay 31, 202485

How it is read

Names in the registry

  • “HRS-5635 Injection”, 6 entries
  • “HRS-5635”, 3 entries
  • “HRS-5635 Injection (low dose) and Peg-IFN-α”, 1 entry
  • “HRS-5635 Injection (high dose) and Peg-IFN-α”, 1 entry
  • “HRS-5635 Injection with Peg-IFN-α”, 1 entry

Codes read as this program: HRS5635.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.